Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Horizon was featured on Cramer:
News @ HZNP
Horizon Pharma plc Announces Issuance of VIMOVO(R) Related Patent with Protection to 2031 from United States Patent and Trademark Office
"This patent significantly expands the strength of the VIMOVO patent estate and extends patent protection out to 2031," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "In addition, this patent exhibits our commitment to innovation and ability to further strengthen the intellectual property protection of our portfolio of drugs. This is an important milestone in the commercial lifecycle for VIMOVO."
http://finance.yahoo.com/news/horizon-pharma-plc-announces-issuance-210500771.html
Investor 100
Thanks for sharing.
Looks like it's getting to a major resistance area. Would like to see that break first.
Stockcharts @ HZNP
Full chart...headed to high teens..fell...bought ...upward..
Horizon Pharma plc Provides Business Update
Expands Sales Organization, Accelerates Expansion of Prescriptions-Made-Easy(TM) (PME) Program and Launches PENNSAID(R)2% in United States; Secures Agreement With FDA on ACTIMMUNE(R) Phase 3 Clinical Trial Primary Endpoint
http://finance.yahoo.com/news/horizon-pharma-plc-provides-business-130000001.html
Incestor 100
Thanks. Watching closely for an entry. Just concerned it's run hard already.
Horizon Pharma plc to Host Fourth Quarter 2014 Conference Call and Webcast on February 27, 2015
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
Investor 100
Nice pick. You think this is getting a little overbought?
Steady Climb @ HZNP
Slow and steady upward...solid start to 2015!
http://openinsider.com/search?q=hznp
Investor 100
Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an ANDA Against PENNSAID(R) 2%
http://finance.yahoo.com/news/horizon-pharma-plc-files-patent-180000945.html
Investor 100
HZNP:
Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day
Data Also Presented on VIMOVO(R) (Naproxen/Esomeprazole Magnesium) in Reducing Knee Osteoarthritis Pain During the 2014 ACR/ARHP Annual Meeting
http://finance.yahoo.com/news/horizon-pharma-plc-announces-presentation-210500565.html
http://finance.yahoo.com/news/horizon-pharma-plc-present-26th-130000187.html
Investor 100
Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE® (Interferon gamma-1b) in Friedreich's Ataxia
DUBLIN, IRELAND--(Marketwired - Oct 3, 2014) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for ACTIMMUNE® (Interferon gamma-1b) for the treatment of Friedreich's ataxia (FA), a rare, genetic disease for which there are currently no approved treatments.
The U.S. Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition that affects fewer than 200,000 patients in the United States. Orphan designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan-drug designation is not subject to the Prescription Drug User Fee Act (PDUFA) fees. The designation may provide ACTIMMUNE, if approved for the treatment of FA, with seven years of market exclusivity for this indication.
FA is a debilitating, life-shortening, degenerative neuro-muscular disorder that affects about one in 50,000 people in the United States. Onset of symptoms can vary from five years old to adulthood, with the childhood onset tending to be associated with a more rapid progression. A progressive loss of coordination and muscle strength leads to motor incapacitation and often the full-time use of a wheelchair. Most young people diagnosed with FA require mobility aids such as a cane, walker or wheelchair by their teens or early 20's.
"This orphan-drug designation for ACTIMMUNE is an important regulatory advancement as we build our development program in FA, a rare, debilitating disorder with no currently approved treatments," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We look forward to the release of results from a Phase 2 study sponsored by the Friedreich's Ataxia Research Alliance (FARA) and conducted at Children's Hospital of Philadelphia."
About ACTIMMUNE®
ACTIMMUNE is currently approved for two rare diseases in the United States. It is approved by the FDA to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD), a genetic disorder that affects the functioning of a type of white blood cell of the immune system, neutrophils or phagocytes, leading to recurrent severe bacterial and fungal infections and chronic inflammatory conditions. In addition, ACTIMMUNE is approved by the FDA to slow the worsening of severe, malignant osteopetrosis (SMO), a genetic disorder, that affects normal bone formation causing the abnormal accumulation of bone material which tends to narrow the space inside bones where bone marrow is formed. This can cause failure of the bone marrow, leading to a decrease in various blood cells such as red blood cells and white blood cells. For more information, please visit www.ACTIMMUNE.com.
Important Safety Information
ACTIMMUNE is contraindicated in patients who develop or have known hypersensitivity to interferon-gamma, E. coli-derived products, or any component of the product.
The most common adverse experiences occurring with ACTIMMUNE therapy are "flu like", or constitutional symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues. Some of the "flu-like" symptoms may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache.
Reversible neutropenia and thrombocytopenia have been observed during ACTIMMUNE therapy. Caution should be exercised when administering ACTIMMUNE in patients with myelosuppression or in combination with other potentially myelosuppressive agents. ACTIMMUNE may also depress hepatic metabolism of certain drugs that are metabolized by the hepatic cytochrome P-450 system. ACTIMMUNE has not been tested for carcinogenic potential. ACTIMMUNE is pregnancy Category C and it is unknown if ACTIMMUNE is excreted in human milk.
Reversible elevations of AST and/or ALT have been observed during ACTIMMUNE therapy. Patients begun on ACTIMMUNE therapy before one year of age should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified.
At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions or may cause reversible neurological effects such as decreased mental status, gait disturbance and dizziness. Therefore, caution is advised when ACTIMMUNE is administered to patients with seizure disorders or compromised CNS function or when administered to patients with cardiac conditions such as ischemia, heart failure or arrhythmia.
For more information on ACTIMMUNE, please see the Full Prescribing Information at www.ACTIMMUNE.com.
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential implications of Orphan Drug designation for ACTIMMUNE in FA, results of a Phase 2 study with ACTIMMUNE and the Company's future development plans for ACTIMMUNE in FA. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding whether Horizon will be able to realize the anticipated benefits of Orphan Drug designation, whether the results of the Phase 2 clinical trial of ACTIMMUNE in FA will warrant further development, and Horizon's ability to obtain regulatory approval for and successfully commercialize ACTIMMUNE for the treatment of FA. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
CONTACT INFORMATION
Contact:
Company:
Elizabeth M. Higashi, CFA
Vice President, Investor Relations
Email Contact
+ 1-224-383-3285
HZNP @ Stockcharts
Been a great trading stock this year and again moving up..
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets
http://finance.yahoo.com/news/horizon-pharma-announces-u-patent-113000830.html Good till 2027!
Investor 100
HZNP : Nice movement upwards with an 8% gain!
HZNP @ Stockcharts
Buying a starter on this dip!
http://www.thestreet.com/story/12823392/1/why-horizon-pharmaceuticals-hznp-is-plummeting-today.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- Horizon Pharmaceuticals (HZNP_) plummeted Monday after the company said CVS Caremark (CVS_) and Express Scripts (ESRX_) would put Horizon's two best-selling drugs on their exclusion lists at the beginning of 2015.
The move to the exclusion list means patients would incur more of a cost for the drugs unless they switch to cheaper alternatives. CVS and Express Scripts are the largest and second-largest pharmacy benefit managers in the U.S.
The two drugs are Duexis, which treats arthritis pains for those with stomach issues, and Vimovo, which treats osteoporosis and rheumatoid arthritis. Horizon acquired the U.S. rights to Vimovo from AstraZeneca (AZN_) in November.
HZNP @ Stockcharts
http://finance.yahoo.com/news/horizon-pharma-present-jmp-securities-113000652.html
http://seekingalpha.com/article/2271233-horizon-pharma-can-it-double-again
Stock has been a winner all year!
Investor 100
Horizon Pharma, Inc. [$HZNP] due diligence
bull flag breakout (or pennant), looks like it is forming a W pattern
$HZNP
DD Notes ~ http://www.ddnotesmaker.com/HZNP
##### recent news/filings ~ source: finance.yahoo.com
Thu, 29 May 2014 13:42:59 GMT ~ Substance Over Style: How Niche Companies Alliqua And Horizon Are Being Overlooked
read full: http://seekingalpha.com/article/2243483-substance-over-style-how-niche-companies-alliqua-and-horizon-are-being-overlooked?source=yahoo
*********************************************************
Thu, 29 May 2014 10:56:10 GMT ~ Horizon Pharma (HZNP): An Off-the-Radar Potential Winner
read full: http://finance.yahoo.com/news/horizon-pharma-hznp-off-radar-105610701.html
*********************************************************
Tue, 27 May 2014 11:30:00 GMT ~ Horizon Pharma to Present at the Jefferies 2014 Global Healthcare Conference
[Marketwired] - Horizon Pharma, Inc. today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at ...
read full: http://finance.yahoo.com/news/horizon-pharma-present-jefferies-2014-113000115.html
*********************************************************
Fri, 23 May 2014 21:10:00 GMT ~ Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
[Marketwired] - Horizon Pharma, Inc. today announced that on May 23, 2014 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 21,000 shares of ...
read full: http://finance.yahoo.com/news/horizon-pharma-reports-inducement-grants-211000987.html
*********************************************************
Mon, 19 May 2014 15:00:10 GMT ~ AstraZeneca's Rejection Shows Stakes Are High for Inversion Deals
read full: http://blogs.wsj.com/moneybeat/2014/05/19/astrazenecas-rejection-shows-stakes-are-high-for-inversion-deals/?mod=yahoo_hs
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/HZNP/company-info
Ticker: $HZNP
OTC Market Place: Not Available
CIK code: not found
Company name: Horizon Pharma, Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/HZNP/filings
Latest financials: http://www.otcmarkets.com/stock/HZNP/financials
Latest news: http://www.otcmarkets.com/stock/HZNP/news - http://finance.yahoo.com/q/h?s=HZNP+Headlines
Major holdings: http://data.cnbc.com/quotes/HZNP/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=HZNP+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/HZNP.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=HZNP
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=HZNP&search=search
DTCC: http://search2.dtcc.com/?q=Horizon+Pharma%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Horizon+Pharma%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Horizon+Pharma%2C+Inc.&x=0&y=0
Short Sales: http://www.otcmarkets.com/stock/HZNP/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/HZNP/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/HZNP/research
Historical Prices: http://finance.yahoo.com/q/hp?s=HZNP+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=HZNP+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=HZNP+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=HZNP+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=HZNP+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=HZNP+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=HZNP
Balance Sheet: http://finance.yahoo.com/q/bs?s=HZNP
Cash Flow: http://finance.yahoo.com/q/cf?s=HZNP+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/HZNP
Bloomberg: http://www.bloomberg.com/quote/HZNP:US
Morningstar: http://quotes.morningstar.com/stock/s?t=HZNP
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HZNP
Barchart: http://www.barchart.com/quotes/stocks/HZNP
OTC Short Report: http://otcshortreport.com/index.php?index=HZNP
Investopedia: http://www.investopedia.com/markets/stocks/HZNP/?wa=0
http://www.pennystocktweets.com/stocks/profile/HZNP
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/HZNP
Not good..
DE VAERE ROBERT J EVP & CFO May 19 Sale 12.94 12,939 167,431 88,555 May 21 05:47 PM
SHERMAN JEFFREY W EVP & Chief Medical Officer May 19 Sale 12.94 9,361 121,131 93,235 May 21 05:46 PM
SMITH TODD N EVP & Chief Commercial Officer May 19 Sale 12.94 10,159 131,457 44,552 May 21 05:45 PM
Walbert Timothy P President, Chairman and CEO May 19 Sale 12.94 31,742 410,741 148,930 May 21 05:44 PM
HZNP @ Stockcharts
A 2014 beastly run indeed...called it early got in at $8.50 2nd round..looking for $20!
Horizon Pharma to Host Corporate Update Meeting on March 27, 2014
http://finance.yahoo.com/news/horizon-pharma-host-corporate-meeting-113000527.html
HZNP @ Stockcharts
All indicators point upward..MFI..MACD..RSI..Follow the money given this is up 65% since I joined the board!
Buy Horizon Pharma On Upcoming Revenue Growth
http://seekingalpha.com/article/2069783-buy-horizon-pharma-on-upcoming-revenue-growth?source=yahoo
http://openinsider.com/search?q=hznp
Great information on the yahoo message board also!
HZNP @ Stockcharts
Been a solid winner in 2014...MFI..follow the money!
Why Horizon Pharma (HZNP) Is Up Today
http://www.thestreet.com/story/12283349/1/why-horizon-pharma-hznp-is-up-today.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- Horizon Pharma (HZNP_) was rising 18.82% to $10.10 in afternoon trading on Wednesday after the pharmaceutical company announced its preliminary results for the fourth quarter and fiscal year 2013.
The company expects total net revenues to be between $31.9 million and $32.4 million for the fourth quarter and between $79.5 million and $80 million for the fiscal year. The company also provided an update on the status of its osteoarthritis drug VIMOVO and announced that all required FDA transfers, including the New Drug Application (NDA) and Investigational New Drug (IND), have been completed. Furthermore, Horizon-labeled inventory "has been manufactured, shipped and sold into the wholesale and pharmacy channel," according to the company's statement.
Why am I making money in this other than a break out from consolidation?
Followers
|
41
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
689
|
Created
|
09/06/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |